Arvinas Inc logo

ARVNArvinas Inc

NASDAQ · Healthcare · Biotechnology

$9.30

+$0.02 (+0.22%)

Arvinas Inc (ARVN) is a biotechnology company listed on NASDAQ. It is led by Randy Teel Ph.D., based in 5 Science Park, New Haven, CT, United States, 06511, with about 246 employees. Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Latest reported ARVN revenue for 2025-09-30 was $41.9M. Net income was -$35.1M. Revenue was up 87.1% from 2025-06-30 to 2025-09-30. ARVN currently screens at market cap $478.7M.

Use this ARVN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ARVN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ARVN SEC filings page. Lician reads the product cache first so this HTML stays unique to Arvinas Inc even when a live quote feed is slow.

About Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

ARVN Key Statistics

Market Cap

$478.75M

Volume

500,089

Previous Close

$9.37

Day Range

$9.06$9.39

00

EPS

-$2.77

Revenue

$263.40M

Net Income

-$198.90M

Gross Profit

$0.00

Free Cash Flow

$0.00

Revenue Growth

+235.5%

Profit Margin

-75.5%

Employees

246

ARVN Financials

Annual income statement in USD. Latest reported periods first.

ARVN annual income statement across FY2024, FY2023, FY2022, FY2021
LineFY2024FY2023FY2022FY2021
Revenue$263.40M$78.50M$131.40M$53.60M
Cost of Revenue$0.00$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00$0.00
Operating Income$0.00$0.00$0.00$0.00
Net Income-$198.90M-$367.30M-$282.50M-$191.00M
EPS (Diluted)-$2.77-$6.62-$5.31-$3.82

Total Assets

$1.09B

Total Debt

$0.00

Shareholders' Equity

$0.00

Cash & Equivalents

$100.50M

Operating Cash Flow

-$259.30M

Free Cash Flow

$0.00

Arvinas Inc Company Information

CEO, President & Director
Randy Teel Ph.D.
Headquarters
5 Science Park, New Haven, CT, United States, 06511
Phone
203 535 1456
IPO / Founded
2018-09-27
Industry
Biotechnology
Data Updated:

Upcoming Events for ARVN